ArticleJCO clinical cancer informatics2025
Bayesian Counterfactual Machine Learning Individualizes Radiation Modality Selection to Mitigate Immunosuppression.
Article in JCO clinical cancer informatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeLymphocytes play critical roles in cancer immunity and tumor surveillance. Radiation-induced lymphopenia (RIL) is a common side effect observed in patients with cancer undergoing chemoradiation therapy (CRT), leading to impaired immunity and worse clinical outcomes. Although proton beam therapy (PBT) has been suggested to reduce RIL risk compared with intensity-modulated radiation therapy (IMRT), this study used Bayesian counterfactual machine learning to identify distinct patient profiles and inform personalized radiation modality choice.
methodsA novel Bayesian causal inferential technique is introduced and applied to a matched retrospective cohort of 510 patients with esophageal cancer undergoing CRT to identify patient profiles for which immunosuppression could have been mitigated from radiation modality selection.
resultsBMI, age, baseline absolute lymphocyte count (ALC), and planning target volume determined the extent to which reductions in ALCs varied by radiation modality. Five patient profiles were identified. Significant variation in ALC nadir between PBT and IMRT was observed in three of the patient subtypes. Notably, older patients (age >69 years) with normal weight experienced a two-fold reduction in mean ALC nadir when treated with IMRT versus PBT. Mean ALC nadir was reduced significantly for IMRT patients with lower ALC at baseline (<1.6 k/µL) who were overweight or obese when compared with PBT, whereas overweight patients with higher baseline ALC showed clinical equipoise between modalities.
conclusionIndividualized radiation therapy selection can be an important tool to minimize immunosuppression for high-risk patients. The Bayesian counterfactual modeling techniques presented in this article are flexible enough to capture complex, nonlinear patterns while estimating interpretable patient profiles for translation into clinical protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.